- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Prostate cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 361KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 55KB)
Cabazitaxel – March 2022
Cabazitaxel: Solution concentrate for I.V. infusion 60 mg in 3 mL; Cabazitaxel Accord®
Last updated
1 July 2022